{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:44:30Z","timestamp":1776213870770,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Projects in Knowledge"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10620-018-5074-8","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T21:19:28Z","timestamp":1525727968000},"page":"2547-2554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness"],"prefix":"10.1007","volume":"63","author":[{"given":"Laura","family":"Jopson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amardeep","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Rudell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Corrigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"5074_CR1","first-page":"1615","volume":"56","author":"DEJ Jones","year":"2007","unstructured":"Jones DEJ. Pathogenesis of primary biliary cirrhosis. Gut. 2007;56:1615\u20131624.","journal-title":"Gut"},{"key":"5074_CR2","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/ije\/26.4.830","volume":"26","author":"JV Metcalf","year":"1997","unstructured":"Metcalf JV, Bhopal RS, Gray J, James OFW. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle-upon-Tyne, England. Int J Epidemiol. 1997;26:830\u2013836.","journal-title":"Int J Epidemiol"},{"key":"5074_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3109\/00365528509089711","volume":"20","author":"J Loufgren","year":"1985","unstructured":"Loufgren J, Jaurnerot G, Danielsson D, Hemdal I. Incidence and prevalence of primary biliary cirrhosis in a denned population in Sweden. Scand J Gastroenterol. 1985;20:647\u2013650.","journal-title":"Scand J Gastroenterol"},{"key":"5074_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/hep.1840110317","volume":"11","author":"A Danielsson","year":"1990","unstructured":"Danielsson A, Boqvist L, Uddenfeldt P. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology. 1990;11:458\u2013464.","journal-title":"Hepatology"},{"key":"5074_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1053\/gast.2000.20197","volume":"119","author":"WR Kim","year":"2000","unstructured":"Kim WR, Lindor KD, Locke GR, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119:1631\u20131636.","journal-title":"Gastroenterology"},{"key":"5074_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"RE Poupon","year":"1997","unstructured":"Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884\u2013890.","journal-title":"Gastroenterology"},{"key":"5074_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.09.018","volume":"51","author":"U Beuers","year":"2009","unstructured":"Beuers U, Boberg KM, Chazouilleres O, et al. EASL practice guidelines on management of cholestatic liver diseases. J Hepatol. 2009;51:237\u2013267.","journal-title":"J Hepatol"},{"key":"5074_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291\u2013308.","journal-title":"Hepatology."},{"key":"5074_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715\u2013720.","journal-title":"Gastroenterology"},{"key":"5074_CR10","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","volume":"102","author":"Y Gong","year":"2007","unstructured":"Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007;102:1799\u20131807.","journal-title":"Am J Gastroenterol"},{"key":"5074_CR11","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","volume":"144","author":"M Carbone","year":"2013","unstructured":"Carbone M, Mells G, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastorenterology. 2013;144:560\u2013569.","journal-title":"Gastorenterology"},{"key":"5074_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"GM Hirschfield","year":"2017","unstructured":"Hirschfield GM, Beuers U, Corpechot C, et al. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145\u2013172.","journal-title":"J Hepatol"},{"key":"5074_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.10.018","author":"M Lu","year":"2017","unstructured":"Lu M, Li J, Haller IV, Romanelli RJ, et al. Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems. Clin Gastroenterol Hepatol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2017.10.018\n                    \n                  .","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5074_CR14","doi-asserted-by":"publisher","first-page":"S525","DOI":"10.1016\/S0168-8278(14)61463-X","volume":"60","author":"F Nevens","year":"2014","unstructured":"Nevens F, Andreone P, Mazzella G, et al. The first primary biliary cirrhosis (PBC) phase 3 trial in two decades-an international study of the FXR agonist obeticholic acid. J Hepatol. 2014;60:S525\u2013S526.","journal-title":"J Hepatol"},{"key":"5074_CR15","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/hep.26018","volume":"57","author":"A Honda","year":"2013","unstructured":"Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57:1931\u20131941.","journal-title":"Hepatology"},{"key":"5074_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","volume":"38","author":"T Kanda","year":"2003","unstructured":"Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol. 2003;38:573\u2013578.","journal-title":"J Gastroenterol"},{"key":"5074_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ajg.2013.51","volume":"108","author":"RP Myers","year":"2014","unstructured":"Myers RP, Swain MG, Lee SS, Shaheen AAM, Burak KW. B-cell depletion with Rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol. 2014;108:933\u2013941.","journal-title":"Am J Gastroenterol"},{"key":"5074_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/hep.24748","volume":"55","author":"M Tsuda","year":"2012","unstructured":"Tsuda M, Moritoki Y, Lian Z-X, et al. Biochemical and immunologic effects of Rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2012;55:512\u2013521.","journal-title":"Hepatology"},{"key":"5074_CR19","first-page":"526A","volume":"62","author":"M Corrigan","year":"2015","unstructured":"Corrigan M, Vale L, Coughlan D, Jones D, Hirschfield G. Clinician confidence in stratifying risk in primary biliary cirrhosis-a Uk-pbc survey. Hepatology. 2015;62:526A.","journal-title":"Hepatology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5074-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5074-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T16:39:50Z","timestamp":1557419990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5074-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["5074"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5074-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"1 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}